Raymond M Reilly Selected Research

Epidermal Growth Factor (EGF)

8/2021	Dose predictions for [177Lu]Lu-DOTA-panitumumab F(ab')2 in NRG mice with HNSCC patient-derived tumour xenografts based on [64Cu]Cu-DOTA-panitumumab F(ab')2 - implications for a PET theranostic strategy.
11/2020	Radioimmunotherapy of PANC-1 human pancreatic cancer xenografts in NOD/SCID or NRG mice with Panitumumab labeled with Auger electron emitting, 111In or β-particle emitting, 177Lu.
1/2020	Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
1/2020	Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with 177Lu Is More Potent for Killing Human Breast Cancer Cells That Coexpress HER2 and EGFR Than Single-Receptor-Targeted (SRT) Radiation Nanomedicines.
1/2017	64Cu-Labeled Trastuzumab Fab-PEG24-EGF Radioimmunoconjugates Bispecific for HER2 and EGFR: Pharmacokinetics, Biodistribution, and Tumor Imaging by PET in Comparison to Monospecific Agents.
3/2016	Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
12/2015	A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
11/2015	Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
3/2014	Intracellular routing in breast cancer cells of streptavidin-conjugated trastuzumab Fab fragments linked to biotinylated doxorubicin-functionalized metal chelating polymers.
1/2014	Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raymond M Reilly Research Topics

Disease

78	Neoplasms (Cancer) 01/2022 - 12/2002
69	Breast Neoplasms (Breast Cancer) 10/2021 - 09/2003
11	Body Weight (Weight, Body) 11/2020 - 09/2003
7	Ovarian Neoplasms (Ovarian Cancer) 01/2021 - 09/2005
6	Pancreatic Neoplasms (Pancreatic Cancer) 11/2020 - 02/2015
6	Leukemia 10/2016 - 09/2011
5	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 10/2018 - 05/2006
3	Myeloid Leukemia (Leukemia, Myelocytic) 05/2014 - 05/2006
2	Brain Neoplasms (Brain Tumor) 10/2021 - 10/2011
2	Inflammation (Inflammations) 10/2011 - 09/2005
2	Infertility (Sterility) 01/2011 - 04/2004
1	Central Nervous System Diseases (CNS Diseases) 10/2021
1	Squamous Cell Carcinoma of Head and Neck 08/2021
1	Triple Negative Breast Neoplasms 01/2020
1	Chromosome Aberrations (Chromosome Abnormalities) 10/2019
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 10/2016
1	Ductal Carcinoma 07/2013
1	Carcinoma (Carcinomatosis) 07/2013

Drug/Important Bio-Agent (IBA)

37	Trastuzumab (Herceptin)FDA Link 10/2021 - 01/2005
26	Epidermal Growth Factor (EGF)IBA 08/2021 - 12/2002
20	Immunoconjugates (Immunoconjugate)IBA 01/2021 - 03/2006
16	Monoclonal AntibodiesIBA 10/2021 - 05/2006
14	Peptides (Polypeptides)IBA 01/2021 - 03/2006
13	Pentetic Acid (DTPA)FDA LinkGeneric 01/2020 - 04/2004
12	Immunoglobulin G (IgG)IBA 01/2018 - 12/2002
10	PolymersIBA 01/2019 - 05/2012
10	GoldIBA 01/2017 - 12/2010
10	ErbB Receptors (EGF Receptor)IBA 03/2016 - 09/2003
10	Immunoglobulin Fab FragmentsIBA 11/2015 - 01/2005
9	MetalsIBA 01/2019 - 10/2005
8	Panitumumab (Vectibix)FDA Link 08/2021 - 02/2015
8	CreatinineIBA 11/2020 - 09/2003
7	MicellesIBA 01/2021 - 09/2007
7	Alanine Transaminase (SGPT)IBA 11/2020 - 09/2003
7	Saline SolutionIBA 05/2020 - 09/2003
7	AcidsIBA 12/2016 - 09/2003
7	Proteins (Proteins, Gene)FDA Link 04/2013 - 04/2004
6	Radioisotopes (Radionuclides)IBA 11/2017 - 05/2005
6	RadiopharmaceuticalsIBA 03/2010 - 09/2003
5	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 08/2021 - 02/2012
5	Pharmaceutical PreparationsIBA 01/2021 - 09/2007
5	pertuzumabIBA 01/2021 - 08/2009
5	Chelating AgentsIBA 01/2019 - 10/2005
5	EpitopesIBA 11/2014 - 03/2006
4	Polyethylene Glycols (Polyethylene Glycol)FDA LinkGeneric 01/2022 - 04/2016
4	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2007 - 09/2005
3	His-His-His-His-His-His ((His)6)IBA 01/2021 - 05/2007
3	Ado-Trastuzumab EmtansineIBA 05/2020 - 01/2018
3	nimotuzumabIBA 01/2020 - 08/2012
3	DNA (Deoxyribonucleic Acid)IBA 10/2019 - 03/2009
3	Interleukin-3 Receptors (Interleukin 3 Receptor)IBA 10/2018 - 09/2011
3	StreptavidinIBA 11/2015 - 01/2013
3	Nuclear Localization Signals (Nuclear Localization Signal)IBA 11/2013 - 08/2012
3	LigandsIBA 01/2013 - 09/2007
2	neodymium pyrocatechin disulfonate (NPD)IBA 10/2017 - 12/2016
2	human ERBB2 proteinIBA 11/2015 - 12/2012
2	Doxorubicin (Adriamycin)FDA LinkGeneric 03/2014 - 03/2010
2	Hormones (Hormone)IBA 01/2013 - 09/2003
2	scyllitol (scyllo-inositol)IBA 10/2011 - 10/2009
2	hippuryl-glycyl-glycine (HIGG)IBA 07/2010 - 08/2009
2	Hemoglobins (Hemoglobin)IBA 07/2010 - 09/2003
2	Methotrexate (Mexate)FDA LinkGeneric 03/2010 - 09/2008
2	Cyclin-Dependent Kinases (cdk Proteins)IBA 10/2009 - 09/2006
2	AntibodiesIBA 04/2009 - 09/2006
2	111In-DTPA-human epidermal growth factorIBA 08/2008 - 06/2006
2	Messenger RNA (mRNA)IBA 02/2008 - 09/2003
2	Tumor Viral Antigens (Large T Antigen)IBA 08/2007 - 05/2006
2	Cyclin-Dependent Kinase Inhibitor p21IBA 03/2007 - 09/2006
2	tat Gene Products (tat Protein)IBA 01/2007 - 09/2006
2	WK-X-34IBA 11/2006 - 07/2006
1	POEGMAIBA 01/2022
1	rucaparibIBA 05/2020
1	1,4,7- triazacyclononane- N,N',N''- triacetic acid (NOTA)IBA 05/2020
1	Gemcitabine FDA Link 05/2020
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 05/2020
1	Liposomes (Liposome)IBA 11/2017
1	SuspensionsIBA 10/2017
1	AntigensIBA 01/2017
1	Biological ProductsIBA 12/2015
1	Indicators and Reagents (Reagents)IBA 01/2015
1	CSL360IBA 11/2014
1	2- (1- hydroxyundecyl)- 1- (4- nitrophenylamino)- 6- phenyl- 6,7a- dihydro- 1H- pyrrolo(3,4- b)pyridine- 5,7(2H,4aH)- dioneIBA 05/2014
1	Polynucleotide 5'-Hydroxyl-Kinase (Kinase, Polynucleotide)IBA 05/2014
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 05/2014
1	ChromatinIBA 03/2014
1	butyl phosphorotrithioate (DEF)IBA 11/2013
1	Dendrimers (Dendrons)IBA 08/2013
1	111In-DTPA-trastuzumabIBA 07/2013
1	GABA-A Receptors (GABA(A) Receptor)IBA 04/2013
1	AnionsIBA 01/2013
1	Biotin (Vitamin H)FDA Link 01/2013
1	histidine-rich proteinsIBA 12/2012

Therapy/Procedure

17	Therapeutics 01/2021 - 09/2006
13	Radioimmunotherapy 08/2021 - 02/2006
12	Radiotherapy 01/2020 - 05/2007
5	Precision Medicine 08/2021 - 11/2014
2	Brachytherapy 12/2016 - 01/2016
2	Injections 08/2012 - 09/2004
1	Neoadjuvant Therapy 01/2016
1	Aftercare (After-Treatment) 05/2014